The Latest
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Iambic Therapeutics, a Nvidia-backed AI drug discovery specialist, is one of three biotechs that have publicly revealed IPO plans since last Friday.
Updated 4 hours ago -
Permission granted by Walgreens
Sponsored by Walgreens Specialty PharmacyBehind the outcomes: How whole-patient support is reshaping oncology care
As oncology care grows personalized and home-based, support around treatment becomes as vital as treatment.
-
Getty Images
News roundupAn orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
-
Getty Images
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.
-
Getty Images
Beacon eye gene therapy hits mark in late-stage study
Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.
-
Permission granted by Novo Nordisk
Obesity drugsNovo talks up drug launches in effort to win back investors
At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.
-
Getty Images
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.
-
Getty Images
Xenon shares fall following depression trial pause
The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.
-
Getty Images
News roundup
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
-
Getty Images
IPO windowElectra amasses $350M in biotech’s latest big IPO
Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.
-
Getty Images
Lisata deal propels Marea’s drug pipeline to Wall Street
Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.
-
Getty Images
Emerging biotechNorth Immunology joins biotech reverse merger boom with Aethlon deal
Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.
-
Getty Images
Emerging biotechRoche, Dualitas team up to find bispecific drugs for immune diseases
Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
-
Getty Images
Novartis to pay $125M for blood-brain barrier crossing platform
Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.
-
Permission granted by Faeth Therapeutics
Deep DiveA booming business on Wall Street would love more biotechs to quietly die
Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
-
Alamy
Obesity drugsNovo partners with Orbis, deepening investment in oral peptide drugs
The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.
-
Getty Images
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
-
Getty Images
China competitionFDA launches pilot program to speed up early US drug research
First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines into human testing.
-
Getty Images
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
GSK has signed its fifth licensing deal with a China-based drugmaker since the start of 2025, agreeing to pay Chimagen Biosciences up to $750 million for a three-pronged T-cell engager for multiple myeloma.
Updated Sept. 15, 2026 -
Getty Images
Startup launchesSling banks $123M for an experimental thyroid eye disease pill
A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.
-
Getty Images
Skyhawk racks up more support for Huntington’s drug
The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.
-
Getty Images
News roundup
FDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
-
Getty Images
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
-
Getty Images
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
-
Courtesy of Scholar Rock
Scholar Rock SMA drug approved by FDA
Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.
